BUSINESS

Regeneron Takes Over Japan Marketing Authorization for Libtayo from Sanofi

June 4, 2024

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Regeneron Japan said on June 3 that it has succeeded the Japanese marketing authorization for the PD-1 inhibitor Libtayo (cemiplimab) originated by the company from Sanofi, effective the same day, as per their global deal on the rights transfer. Regeneron…

To read the full story

Regeneron Lines Up 5 Late-Stage Assets for Japan: Commercial Head
December 11, 2025
Regeneron Bolsters Japan Oncology Team as Libtayo Gains Ground
October 3, 2025
Regeneron to Upsize Japan Workforce after Libtayo Transfer
February 13, 2025
Sanofi Launches PD-1 Inhibitor Libtayo in Japan
March 31, 2023

BUSINESS

Sumitomo Regains Growth Momentum, Eyes 350 Billion Yen from 2 Key Drugs in FY2028
March 3, 2026
Middle East Turmoil Raises Fears over API Shipments as Key Airports Shut
March 3, 2026
UCB, Daiichi Sankyo to Wind Up Japan Partnership for Vimpat
March 3, 2026
Itochu Snaps Up CoreMed to Bolster Japan Entry Support
March 3, 2026
Ono to Transfer Opalmon, Prostandin to Daito by November
March 3, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…